Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers

This section outlines the general eligibility criteria for applicants, the geographical scope of the program, and its overarching objectives. The program targeted entities capable of advancing precision medicine by clinically validating biomarkers for existing prescription drugs to improve patient outcomes across Europe and internationally, including the United States.

This section details the specific types of projects and thematic areas eligible for funding, focusing on the clinical validation of biomarkers to enhance drug effectiveness. It outlines the scope of research and the maturity level expected for funded projects.

This program provided financial support through grants, with substantial funding available for individual projects focusing on biomarker validation.

Applicants and beneficiaries were subject to a comprehensive set of conditions regarding admissibility, eligibility, consortium formation, and adherence to various regulations, ensuring high standards in project implementation and ethical conduct.

The application process involved a single-stage submission, followed by evaluation and grant agreement procedures, with clear timelines and support resources provided by the European Commission.

This program was established and governed by the comprehensive framework of Horizon Europe, a key funding instrument of the European Union, along with specific regulations pertinent to clinical research.